[Skip to Content]
[Skip to Content Landing]
January 22/29, 2003

Direct-to-Consumer Advertising and Shared Liability for Pharmaceutical Manufacturers

Author Affiliations

Author Affiliation: Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass.

JAMA. 2003;289(4):477-481. doi:10.1001/jama.289.4.477

During the last several years, the marketing of prescription drugs has undergone substantial change, facilitated by changes in the regulatory environment governing direct-to-consumer advertising (DTCA). Since the release in 1997 of new draft guidance by the Food and Drug Administration (FDA),1 consumer-oriented drug marketing has become pervasive, particularly in broadcast media. Ninety-one percent of US individuals report having seen consumer-oriented drug advertisements, and the pharmaceutical industry spent nearly $2.5 billion on DTCA in 2000.2

First Page Preview View Large
First page PDF preview
First page PDF preview